Perceived Barriers to Sacubitril/Valsartan Use in Patients With Heart Failure

Journal of Cardiac Failure - United States
doi 10.1016/j.cardfail.2018.07.378
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Sacubitril-Valsartan in Heart Failure and Multimorbidity Patients

ESC heart failure
Cardiovascular MedicineCardiology
2018English

Reply: Sacubitril/Valsartan for Chagas' Heart Disease Heart Failure?

ESC heart failure
Cardiovascular MedicineCardiology
2018English

Safety of Initiation of Sacubitril/Valsartan in ICU Patients With Advanced Decompensated Heart Failure

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Novel Agent, Sacubitril-Valsartan: Prescribing Patterns and Perceived Barriers to Hospital Formulary Inclusion

Clinical Studies & Medical Case Reports
2019English

Pcv6 - Sacubitril/Valsartan in Heart Failure: Projected Health Outcomes in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Reverse Remodeling Response to Sacubitril/Valsartan Therapy in Heart Failure With Reduced Ejection Fraction

Cardiovascular Therapeutics
MedicineCardiovascular MedicinePharmacologyCardiology
2018English

Tolerability, Safety, and Hemodynamics of Sacubitril-Valsartan in Acutely Decompensated Heart Failure Patients With Cardiogenic Shock

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

The Parasail Study- Canadian Real World Experience Use of Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction

Canadian Journal of Cardiology
Cardiovascular MedicineCardiology
2018English

The Neprilysin Pathway in Heart Failure: A Review and Guide on the Use of Sacubitril/Valsartan

Heart
Cardiovascular MedicineCardiology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy